HARBIN, China, Jan. 21, 2011 /PRNewswire-Asia-FirstCall/ —
China Sky One Medical, Inc. (“China Sky One Medical” or “the
CSKI), a leading fully integrated pharmaceutical company in the
People’s Republic of China (“PRC”), today announced the shareholder
letter from Mr. Yanqing Liu, the Company’s Chairman of Board of
Directors, and Chief Executive Officer. The full text of this
shareholder letter is as follows:
Our company’s reputation continues to be tarnished by unfounded
allegations of certain self-serving investors, whose viewpoints
recently have been rehashed in media outlets, driving our share
price down and create panic among our valued shareholders.
We regret that our faithful shareholders have suffered loss in
the capital market as a result of reckless criticism and attacks.
Most of the issues that recently resurfaced in the media were
raised some time ago and have already been addressed by management.
We have worked closely and diligently with all SEC inquiries and
will continue to do so.
As you know, despite all attempts, China Sky One Medical is one
of China’s leading pharmaceutical companies. We manufacture and
distribute over 100 products across approximately 30,000 pharmacies
and 1,000 hospitals throughout China. We will continue to focus on
delivering strong operating performance, which should provide a key
source of confidence for our shareholders in the long run. So far,
there are not many shareholders who have been visiting the Company,
or met with our management team. Without conducting field research
or seeing firsthand the dedication of our professionals, we
consider the negative challenges have demonstrated little interest
in knowing the business.
China Sky One Medical operates four pharmaceutical factories and
two R&D centers in China. We are well positioned in the